chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19, Coronavirus pneumonia, Vaccine breakthrough infection
Clinical narrative: Narrative: Breakthrough Covid-19: Pneumonia due to coronavirus disease 2019 Acute respiratory failure with hypoxia
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19, COVID-19 pneumonia, Death, Dyspnoea
Clinical narrative: Narrative: HISTORY OF PRESENT ILLNESS: The patient is an 82 y/o male with PMH of HTN, DM, and HLD who presents to ED after a fall. The patient reports that he unintentionally tripped over a curb today and fell. He reports he fell on outstretched hands, he denies other injuries. The patient states that he received the COVID vaccine. He denies fever, chills, SOB, cough, and chest pain. Upon arrival in the ED the patient was tachpnic and hypoxic with oxygen saturations in the 80s. He required 4L supplemental oxygen. COVID-19 testing was positive. HOSPITAL COURSE: PATIENT is an 82 yo M with acute hypoxic respiratory failure secondary to COVID-19 with likely underlying pulmonary fibrosis, on inpatient hospice for progressive dyspnea/hypoxia despite optimal medical treatment for COVID-19 pneumonia. PATIENT continued to decline significantly despite all measures of treatment. Family requested hospice care given grim prognosis. He was provided comfort care. Family was updated and multiple video conferences were completed by social work for visitation during end of life. Patient expired on 9/5/21.
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Fall, Gait disturbance, General physical health deterioration, Hypoxia, Limb injury
Clinical narrative: Narrative: HISTORY OF PRESENT ILLNESS: The patient is an 82 y/o male with PMH of HTN, DM, and HLD who presents to ED after a fall. The patient reports that he unintentionally tripped over a curb today and fell. He reports he fell on outstretched hands, he denies other injuries. The patient states that he received the COVID vaccine. He denies fever, chills, SOB, cough, and chest pain. Upon arrival in the ED the patient was tachpnic and hypoxic with oxygen saturations in the 80s. He required 4L supplemental oxygen. COVID-19 testing was positive. HOSPITAL COURSE: PATIENT is an 82 yo M with acute hypoxic respiratory failure secondary to COVID-19 with likely underlying pulmonary fibrosis, on inpatient hospice for progressive dyspnea/hypoxia despite optimal medical treatment for COVID-19 pneumonia. PATIENT continued to decline significantly despite all measures of treatment. Family requested hospice care given grim prognosis. He was provided comfort care. Family was updated and multiple video conferences were completed by social work for visitation during end of life. Patient expired on 9/5/21.
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Pulmonary fibrosis, SARS-CoV-2 test positive, Tachypnoea
Clinical narrative: Narrative: HISTORY OF PRESENT ILLNESS: The patient is an 82 y/o male with PMH of HTN, DM, and HLD who presents to ED after a fall. The patient reports that he unintentionally tripped over a curb today and fell. He reports he fell on outstretched hands, he denies other injuries. The patient states that he received the COVID vaccine. He denies fever, chills, SOB, cough, and chest pain. Upon arrival in the ED the patient was tachpnic and hypoxic with oxygen saturations in the 80s. He required 4L supplemental oxygen. COVID-19 testing was positive. HOSPITAL COURSE: PATIENT is an 82 yo M with acute hypoxic respiratory failure secondary to COVID-19 with likely underlying pulmonary fibrosis, on inpatient hospice for progressive dyspnea/hypoxia despite optimal medical treatment for COVID-19 pneumonia. PATIENT continued to decline significantly despite all measures of treatment. Family requested hospice care given grim prognosis. He was provided comfort care. Family was updated and multiple video conferences were completed by social work for visitation during end of life. Patient expired on 9/5/21.
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Vaccine breakthrough infection
Clinical narrative: Narrative: Breakthrough COVID infection requiring Hospitalization
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Vaccine breakthrough infection
Clinical narrative: Narrative:  Breakthrough COVID infection requiring hospitalization
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Aortic dilatation, Asthenia, Atypical pneumonia, COVID-19, COVID-19 pneumonia
Clinical narrative: Narrative: Admission Date: AUG 27,2021 Discharge Date: SEP 4,2021 Admit Diagnosis: COVID PNEUMONIA Condition of patient at discharge: Stable 71 yo male presents to Emergency Dept with complaints of fatigue, weakness, myalgias. He reports that he fell earlier due to generalized weakness and just wanted to get checked out. Reports that he tested positive for covid-19 on Sun 08/22 at another urgent care. Reports that he developed a non-productive cough and body aches on Sat 08/21, developed fever and worsening cough on 8/22 which prompted him to seek testing (the first time). He denies fever since 8/22, denies n/v/d/cp/sob/abd pn/back pn/urinary sxs. COVID test positive on admission on 8/27 and CXR with bilateral infiltrates consistent with atypical pneumonia despite being fully vaccinated with Pfizer COVID vaccine on 2/4/2021 and 2/25/2021. Patient completed 10 days of dexamethasone and 10 days of remdesivir while admitted. Patient initially treated for community acquired pneumonia but antibiotics were discontinued shortly after admission due to procal < 0.05. DDimer elevated on admission and patient maintained on therapeutic doses of enoxaparin while admitted. Patient underwent walk test on 9/4 which showed 1L O2 req at rest and 4L O2 req with exertion. At time, he had escalating O2 requirements from 3 to 5L. Patient discharged home on 9/4/2021 with home O2 to isolate until 9/6.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Cough, Dyspnoea, Fall, Fatigue, Hilar lymphadenopathy
Clinical narrative: Narrative: Admission Date: AUG 27,2021 Discharge Date: SEP 4,2021 Admit Diagnosis: COVID PNEUMONIA Condition of patient at discharge: Stable 71 yo male presents to Emergency Dept with complaints of fatigue, weakness, myalgias. He reports that he fell earlier due to generalized weakness and just wanted to get checked out. Reports that he tested positive for covid-19 on Sun 08/22 at another urgent care. Reports that he developed a non-productive cough and body aches on Sat 08/21, developed fever and worsening cough on 8/22 which prompted him to seek testing (the first time). He denies fever since 8/22, denies n/v/d/cp/sob/abd pn/back pn/urinary sxs. COVID test positive on admission on 8/27 and CXR with bilateral infiltrates consistent with atypical pneumonia despite being fully vaccinated with Pfizer COVID vaccine on 2/4/2021 and 2/25/2021. Patient completed 10 days of dexamethasone and 10 days of remdesivir while admitted. Patient initially treated for community acquired pneumonia but antibiotics were discontinued shortly after admission due to procal < 0.05. DDimer elevated on admission and patient maintained on therapeutic doses of enoxaparin while admitted. Patient underwent walk test on 9/4 which showed 1L O2 req at rest and 4L O2 req with exertion. At time, he had escalating O2 requirements from 3 to 5L. Patient discharged home on 9/4/2021 with home O2 to isolate until 9/6.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Lung infiltration, Myalgia, Pain, Pneumonia, Pyrexia
Clinical narrative: Narrative: Admission Date: AUG 27,2021 Discharge Date: SEP 4,2021 Admit Diagnosis: COVID PNEUMONIA Condition of patient at discharge: Stable 71 yo male presents to Emergency Dept with complaints of fatigue, weakness, myalgias. He reports that he fell earlier due to generalized weakness and just wanted to get checked out. Reports that he tested positive for covid-19 on Sun 08/22 at another urgent care. Reports that he developed a non-productive cough and body aches on Sat 08/21, developed fever and worsening cough on 8/22 which prompted him to seek testing (the first time). He denies fever since 8/22, denies n/v/d/cp/sob/abd pn/back pn/urinary sxs. COVID test positive on admission on 8/27 and CXR with bilateral infiltrates consistent with atypical pneumonia despite being fully vaccinated with Pfizer COVID vaccine on 2/4/2021 and 2/25/2021. Patient completed 10 days of dexamethasone and 10 days of remdesivir while admitted. Patient initially treated for community acquired pneumonia but antibiotics were discontinued shortly after admission due to procal < 0.05. DDimer elevated on admission and patient maintained on therapeutic doses of enoxaparin while admitted. Patient underwent walk test on 9/4 which showed 1L O2 req at rest and 4L O2 req with exertion. At time, he had escalating O2 requirements from 3 to 5L. Patient discharged home on 9/4/2021 with home O2 to isolate until 9/6.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: Narrative: Admission Date: AUG 27,2021 Discharge Date: SEP 4,2021 Admit Diagnosis: COVID PNEUMONIA Condition of patient at discharge: Stable 71 yo male presents to Emergency Dept with complaints of fatigue, weakness, myalgias. He reports that he fell earlier due to generalized weakness and just wanted to get checked out. Reports that he tested positive for covid-19 on Sun 08/22 at another urgent care. Reports that he developed a non-productive cough and body aches on Sat 08/21, developed fever and worsening cough on 8/22 which prompted him to seek testing (the first time). He denies fever since 8/22, denies n/v/d/cp/sob/abd pn/back pn/urinary sxs. COVID test positive on admission on 8/27 and CXR with bilateral infiltrates consistent with atypical pneumonia despite being fully vaccinated with Pfizer COVID vaccine on 2/4/2021 and 2/25/2021. Patient completed 10 days of dexamethasone and 10 days of remdesivir while admitted. Patient initially treated for community acquired pneumonia but antibiotics were discontinued shortly after admission due to procal < 0.05. DDimer elevated on admission and patient maintained on therapeutic doses of enoxaparin while admitted. Patient underwent walk test on 9/4 which showed 1L O2 req at rest and 4L O2 req with exertion. At time, he had escalating O2 requirements from 3 to 5L. Patient discharged home on 9/4/2021 with home O2 to isolate until 9/6.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19 pneumonia, Death, Dyspnoea, Intensive care
Clinical narrative: Narrative:  81 yo M with PMH significant for CKD 3a, RCC s/p L nephrectomy (2016) with hepatic dome mass, psoas mass, and mesenteric nodule, COPD, OSA, and hypothyroidism who was admitted for COVID PNA s/p Pfizer (02/21), initially on 4L NC but with worsening dyspnea and increased spO2 requirements was transferred to ICU 8/11 for higher level of care. Patient was initially placed on HFNC for oxygenation support, but decompensated despite steroid, dexamethasone. Patient eventually was fully BIPAP bound starting 8/22. On 8/27, patient was no longer able to maintain oxygenation >85% despite maximal BIPAP support. We discussed with the family that intubation at this point would just result in further suffering, and that patient is very unlikely to recover from overwhelming COVID PNA. Family decided to withdraw care and patient was placed on comfort care. He passed on 11:02 PM 8/27.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Positive airway pressure therapy
Clinical narrative: Narrative:  81 yo M with PMH significant for CKD 3a, RCC s/p L nephrectomy (2016) with hepatic dome mass, psoas mass, and mesenteric nodule, COPD, OSA, and hypothyroidism who was admitted for COVID PNA s/p Pfizer (02/21), initially on 4L NC but with worsening dyspnea and increased spO2 requirements was transferred to ICU 8/11 for higher level of care. Patient was initially placed on HFNC for oxygenation support, but decompensated despite steroid, dexamethasone. Patient eventually was fully BIPAP bound starting 8/22. On 8/27, patient was no longer able to maintain oxygenation >85% despite maximal BIPAP support. We discussed with the family that intubation at this point would just result in further suffering, and that patient is very unlikely to recover from overwhelming COVID PNA. Family decided to withdraw care and patient was placed on comfort care. He passed on 11:02 PM 8/27.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Acute kidney injury, Asthenia, COVID-19, Hypovolaemia, Intensive care
Clinical narrative: Narrative:  Patient is a 74 y.o M, with significant history of CAD, admitted with concerns for weakness in setting of COVID positivity, also with volume depletion associated acute renal failure. HOSPITAL COURSE: Initially received in MICU, stable on presentation, and downgraded to Covid Ward. Has done well, no cardiopulmonary difficulties, with acute concerns resolved. Discharged to home on 8/22/2021.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: Narrative:  Patient is a 74 y.o M, with significant history of CAD, admitted with concerns for weakness in setting of COVID positivity, also with volume depletion associated acute renal failure. HOSPITAL COURSE: Initially received in MICU, stable on presentation, and downgraded to Covid Ward. Has done well, no cardiopulmonary difficulties, with acute concerns resolved. Discharged to home on 8/22/2021.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:  75 yo male with end stage renal disease on dialysis, cardiomyopathy, HTN, HLD, cognitive impairment living in long term care facility died on 7/29/2021 at REHABILITATION facility. Pt had received covid vaccines on 2/4/21 & 3/6/21. Death appears not related to vaccines due to comorbidities, age, and length of time from vaccine administration.
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: Acute myocardial infarction, Blood pressure decreased, Cardiac failure, Cardiogenic shock, Chest pain
Clinical narrative: Narrative:  84yo MALE with CAD s/p PCI x4 (2017), HFrEF (Echo 8/27/2021 with EF 15-20%,LVdd), HTN, HLD, R ICA 50-69% stenosis via atherosclerotic plaque, T2DM and Stage 3A male L breast Ca presented to the ED on 8/26 after episodes of chest pain while lying abed around 0200. Pt was admitted to agency hospital & diagnosed with NSTEMI and HFrEF exacerbation. renal fxn worsened on 8/31. He became cold and had continuing soft pressures and was transferred to ICU for suspected cariogenic shock on 9/1. Pt was then transfered to another hospital on 9/1/2021 for cardiac intervention procedure. On 9/2/21 patients condition deteriorated. His oxygen requirements went up and he was put on BiPAP. His pressures were dropping with MAP<65, hence levophed was started after consulting with his primary cardiologist andpatient was the transferred to the CCU for further work up and close monitoring.Patient was ultimately Intubated/Sedated. Patient then got Impella assisted PCI of LM into LAD on 9/2/2021. However, overnight patients condition deteriorated and his pressor requirements increased significantly. Family was updatedfrequently. Palliative care was consulted on 9/3/2021 and detailed discussion was done with the children. Children were aware of Patients poor prognosis. Reviewed code status. Children in agreement to revise code status to dnr Comfort care only. Chaplain at bedside to assist with spiritual support. Family Priest was also present. Patient passed away at 13:50 on 9/3/2021. Pt had received covid vaccines on 3/11/2021 & 2/8/2021. Pt's death is not related to covid vaccines.
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: Condition aggravated, Death, Echocardiogram abnormal, Ejection fraction decreased, Endotracheal intubation
Clinical narrative: Narrative:  84yo MALE with CAD s/p PCI x4 (2017), HFrEF (Echo 8/27/2021 with EF 15-20%,LVdd), HTN, HLD, R ICA 50-69% stenosis via atherosclerotic plaque, T2DM and Stage 3A male L breast Ca presented to the ED on 8/26 after episodes of chest pain while lying abed around 0200. Pt was admitted to agency hospital & diagnosed with NSTEMI and HFrEF exacerbation. renal fxn worsened on 8/31. He became cold and had continuing soft pressures and was transferred to ICU for suspected cariogenic shock on 9/1. Pt was then transfered to another hospital on 9/1/2021 for cardiac intervention procedure. On 9/2/21 patients condition deteriorated. His oxygen requirements went up and he was put on BiPAP. His pressures were dropping with MAP<65, hence levophed was started after consulting with his primary cardiologist andpatient was the transferred to the CCU for further work up and close monitoring.Patient was ultimately Intubated/Sedated. Patient then got Impella assisted PCI of LM into LAD on 9/2/2021. However, overnight patients condition deteriorated and his pressor requirements increased significantly. Family was updatedfrequently. Palliative care was consulted on 9/3/2021 and detailed discussion was done with the children. Children were aware of Patients poor prognosis. Reviewed code status. Children in agreement to revise code status to dnr Comfort care only. Chaplain at bedside to assist with spiritual support. Family Priest was also present. Patient passed away at 13:50 on 9/3/2021. Pt had received covid vaccines on 3/11/2021 & 2/8/2021. Pt's death is not related to covid vaccines.
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: Feeling cold, General physical health deterioration, Intensive care, Interventional procedure, Left ventricular dysfunction
Clinical narrative: Narrative:  84yo MALE with CAD s/p PCI x4 (2017), HFrEF (Echo 8/27/2021 with EF 15-20%,LVdd), HTN, HLD, R ICA 50-69% stenosis via atherosclerotic plaque, T2DM and Stage 3A male L breast Ca presented to the ED on 8/26 after episodes of chest pain while lying abed around 0200. Pt was admitted to agency hospital & diagnosed with NSTEMI and HFrEF exacerbation. renal fxn worsened on 8/31. He became cold and had continuing soft pressures and was transferred to ICU for suspected cariogenic shock on 9/1. Pt was then transfered to another hospital on 9/1/2021 for cardiac intervention procedure. On 9/2/21 patients condition deteriorated. His oxygen requirements went up and he was put on BiPAP. His pressures were dropping with MAP<65, hence levophed was started after consulting with his primary cardiologist andpatient was the transferred to the CCU for further work up and close monitoring.Patient was ultimately Intubated/Sedated. Patient then got Impella assisted PCI of LM into LAD on 9/2/2021. However, overnight patients condition deteriorated and his pressor requirements increased significantly. Family was updatedfrequently. Palliative care was consulted on 9/3/2021 and detailed discussion was done with the children. Children were aware of Patients poor prognosis. Reviewed code status. Children in agreement to revise code status to dnr Comfort care only. Chaplain at bedside to assist with spiritual support. Family Priest was also present. Patient passed away at 13:50 on 9/3/2021. Pt had received covid vaccines on 3/11/2021 & 2/8/2021. Pt's death is not related to covid vaccines.
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: Mean arterial pressure decreased, Percutaneous coronary intervention, Positive airway pressure therapy, Renal impairment
Clinical narrative: Narrative:  84yo MALE with CAD s/p PCI x4 (2017), HFrEF (Echo 8/27/2021 with EF 15-20%,LVdd), HTN, HLD, R ICA 50-69% stenosis via atherosclerotic plaque, T2DM and Stage 3A male L breast Ca presented to the ED on 8/26 after episodes of chest pain while lying abed around 0200. Pt was admitted to agency hospital & diagnosed with NSTEMI and HFrEF exacerbation. renal fxn worsened on 8/31. He became cold and had continuing soft pressures and was transferred to ICU for suspected cariogenic shock on 9/1. Pt was then transfered to another hospital on 9/1/2021 for cardiac intervention procedure. On 9/2/21 patients condition deteriorated. His oxygen requirements went up and he was put on BiPAP. His pressures were dropping with MAP<65, hence levophed was started after consulting with his primary cardiologist andpatient was the transferred to the CCU for further work up and close monitoring.Patient was ultimately Intubated/Sedated. Patient then got Impella assisted PCI of LM into LAD on 9/2/2021. However, overnight patients condition deteriorated and his pressor requirements increased significantly. Family was updatedfrequently. Palliative care was consulted on 9/3/2021 and detailed discussion was done with the children. Children were aware of Patients poor prognosis. Reviewed code status. Children in agreement to revise code status to dnr Comfort care only. Chaplain at bedside to assist with spiritual support. Family Priest was also present. Patient passed away at 13:50 on 9/3/2021. Pt had received covid vaccines on 3/11/2021 & 2/8/2021. Pt's death is not related to covid vaccines.
Age: 88.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Narrative:  COVID-19 positive after receiving both doses of Moderna in Jan/Feb 2021 and booster 8/24/21
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19, Coronavirus pneumonia, Vaccine breakthrough infection
Clinical narrative: Narrative: Breakthrough Covid-19: Pneumonia due to coronavirus disease 2019 and acute respiratory failure with hypoxia
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Vaccine breakthrough infection
Clinical narrative: Narrative:  Breakthrough Delta Variant COVID infection requiring hospitalization
Age: 83.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Acute respiratory failure, Atypical pneumonia, COVID-19, COVID-19 pneumonia, Chest X-ray abnormal
Clinical narrative: Narrative:  Admission Date: Sep 9,2021 Discharge Date: Sep 17,2021 Admission diagnosis: acute hypoxic respiratory failure secondary to COVID Condition of patient at discharge: stable 83yo male with past medical history of HTN, hyperlipidemia, type 2 diabetes, CKD III, prostate cancer in surveillance, hypothyroidism, dementia who presented as transfer from another hospital with DKA and acute hypercapnic respiratory failure (AHRF) secondary to COVID on 9/9/2021. AHRF secondary to COVID pneumonia: Patient noted to be hypoxic at Emergency Room to low 80s. Septic on admission. O2 sats stable initially stable at 92% on 7L oxymizer, though increased to high flow nasal cannula. Patient is fully vaccination with Moderna COVID vaccine on 2/26/2021 and 3/23/2021. CXR with patchy bilateral infiltrates. CT c/w multifocal pneumonia and emphysema. Eventually weaned down to RA with 2L O2 on exertion. Home O2 ordered. Procal elevated at 1.5 on admission, completed CAP coverage (rocephin, azithro, Levaquin given renal fx) Completed remdesivir x5 days and given Tocilizumab on 9/10. Give dexamethasone 6mg daily 9/9 x10 days (end date 09/18). Albuterol inh 2 puffs q6h. Inflammatory markers downtrending at discharge.
Age: 83.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Computerised tomogram thorax abnormal, Diabetic ketoacidosis, Emphysema, Hypoxia, Inflammatory marker increased
Clinical narrative: Narrative:  Admission Date: Sep 9,2021 Discharge Date: Sep 17,2021 Admission diagnosis: acute hypoxic respiratory failure secondary to COVID Condition of patient at discharge: stable 83yo male with past medical history of HTN, hyperlipidemia, type 2 diabetes, CKD III, prostate cancer in surveillance, hypothyroidism, dementia who presented as transfer from another hospital with DKA and acute hypercapnic respiratory failure (AHRF) secondary to COVID on 9/9/2021. AHRF secondary to COVID pneumonia: Patient noted to be hypoxic at Emergency Room to low 80s. Septic on admission. O2 sats stable initially stable at 92% on 7L oxymizer, though increased to high flow nasal cannula. Patient is fully vaccination with Moderna COVID vaccine on 2/26/2021 and 3/23/2021. CXR with patchy bilateral infiltrates. CT c/w multifocal pneumonia and emphysema. Eventually weaned down to RA with 2L O2 on exertion. Home O2 ordered. Procal elevated at 1.5 on admission, completed CAP coverage (rocephin, azithro, Levaquin given renal fx) Completed remdesivir x5 days and given Tocilizumab on 9/10. Give dexamethasone 6mg daily 9/9 x10 days (end date 09/18). Albuterol inh 2 puffs q6h. Inflammatory markers downtrending at discharge.
Age: 83.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Lung infiltration, Pneumonia, Pneumonia viral, Procalcitonin, Respiratory failure
Clinical narrative: Narrative:  Admission Date: Sep 9,2021 Discharge Date: Sep 17,2021 Admission diagnosis: acute hypoxic respiratory failure secondary to COVID Condition of patient at discharge: stable 83yo male with past medical history of HTN, hyperlipidemia, type 2 diabetes, CKD III, prostate cancer in surveillance, hypothyroidism, dementia who presented as transfer from another hospital with DKA and acute hypercapnic respiratory failure (AHRF) secondary to COVID on 9/9/2021. AHRF secondary to COVID pneumonia: Patient noted to be hypoxic at Emergency Room to low 80s. Septic on admission. O2 sats stable initially stable at 92% on 7L oxymizer, though increased to high flow nasal cannula. Patient is fully vaccination with Moderna COVID vaccine on 2/26/2021 and 3/23/2021. CXR with patchy bilateral infiltrates. CT c/w multifocal pneumonia and emphysema. Eventually weaned down to RA with 2L O2 on exertion. Home O2 ordered. Procal elevated at 1.5 on admission, completed CAP coverage (rocephin, azithro, Levaquin given renal fx) Completed remdesivir x5 days and given Tocilizumab on 9/10. Give dexamethasone 6mg daily 9/9 x10 days (end date 09/18). Albuterol inh 2 puffs q6h. Inflammatory markers downtrending at discharge.
Age: 83.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: SARS-CoV-2 test positive, Sepsis
Clinical narrative: Narrative:  Admission Date: Sep 9,2021 Discharge Date: Sep 17,2021 Admission diagnosis: acute hypoxic respiratory failure secondary to COVID Condition of patient at discharge: stable 83yo male with past medical history of HTN, hyperlipidemia, type 2 diabetes, CKD III, prostate cancer in surveillance, hypothyroidism, dementia who presented as transfer from another hospital with DKA and acute hypercapnic respiratory failure (AHRF) secondary to COVID on 9/9/2021. AHRF secondary to COVID pneumonia: Patient noted to be hypoxic at Emergency Room to low 80s. Septic on admission. O2 sats stable initially stable at 92% on 7L oxymizer, though increased to high flow nasal cannula. Patient is fully vaccination with Moderna COVID vaccine on 2/26/2021 and 3/23/2021. CXR with patchy bilateral infiltrates. CT c/w multifocal pneumonia and emphysema. Eventually weaned down to RA with 2L O2 on exertion. Home O2 ordered. Procal elevated at 1.5 on admission, completed CAP coverage (rocephin, azithro, Levaquin given renal fx) Completed remdesivir x5 days and given Tocilizumab on 9/10. Give dexamethasone 6mg daily 9/9 x10 days (end date 09/18). Albuterol inh 2 puffs q6h. Inflammatory markers downtrending at discharge.
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Death, Incomplete course of vaccination, SARS-CoV-2 test positive
Clinical narrative: Narrative:  pt died 9/28; prior to receiving the 2nd dose of COVID vaccine; became COVID positive shortly after receiving his first dose.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Death, Loss of personal independence in daily activities
Clinical narrative: Narrative:  66yo male with Chronic left hemiplegia from prior CVA was placed in long term facility due to Self care deficit on Aug 12, 2021 and died at facility on 9/21/2021. No information relayed to agency regarding circumstances of pt's death. Pt had received covid vaccines on 4/8/21 & 5/18/21. Likely vaccines are unrelated to pt's death.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Bacterial vaginosis, Computerised tomogram, Computerised tomogram abnormal, Dizziness
Clinical narrative: Got Moderna COVID-19 vaccine 2 (LOT: 006B21A) and depo-shot and had pain in arm, couldn't out of bed. Then dizziness started. Started to experience UTI and overactive bladder problems-- was then seen in hospital for this on April 4th and April 6th, 2021. Was also hospitalized on April 20th for three days for the same issue- abdominal pain, recurrent UTI, bacterial vaginosis. On May 16th, was seen again in hospital. Will shallow test on November 17, 2021. On November 1, 2021, got an injection (rocephin and lidocaine) at OB-GYN for pelvic inflammatory disease.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Echocardiogram abnormal, Hypertonic bladder, Mobility decreased, Pain in extremity, Pelvic inflammatory disease
Clinical narrative: Got Moderna COVID-19 vaccine 2 (LOT: 006B21A) and depo-shot and had pain in arm, couldn't out of bed. Then dizziness started. Started to experience UTI and overactive bladder problems-- was then seen in hospital for this on April 4th and April 6th, 2021. Was also hospitalized on April 20th for three days for the same issue- abdominal pain, recurrent UTI, bacterial vaginosis. On May 16th, was seen again in hospital. Will shallow test on November 17, 2021. On November 1, 2021, got an injection (rocephin and lidocaine) at OB-GYN for pelvic inflammatory disease.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Sinus tachycardia, Ultrasound scan abnormal, Urinary tract infection
Clinical narrative: Got Moderna COVID-19 vaccine 2 (LOT: 006B21A) and depo-shot and had pain in arm, couldn't out of bed. Then dizziness started. Started to experience UTI and overactive bladder problems-- was then seen in hospital for this on April 4th and April 6th, 2021. Was also hospitalized on April 20th for three days for the same issue- abdominal pain, recurrent UTI, bacterial vaginosis. On May 16th, was seen again in hospital. Will shallow test on November 17, 2021. On November 1, 2021, got an injection (rocephin and lidocaine) at OB-GYN for pelvic inflammatory disease.
Sex: U
Vaccine: FLUX
Symptoms: Chest discomfort
Clinical narrative: 20 grams into the infusion patient started having chest tightness. Infusion was stopped. Symptoms resolved 2 hours post post stopping the infusion. Patient also had a flu shot day before the infusion
Sex: F
Vaccine: COVID19
Symptoms: Product preparation issue
Clinical narrative: Person received undiluted dose of Pfizer vaccine.
Sex: M
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: After the injection I've noticed some odd noises in my ears and that appears to be tinnitus in one or both ears. Either a ringing or a thumping / roaring sound.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Endotracheal intubation, Guillain-Barre syndrome, Hypoaesthesia, Mechanical ventilation
Clinical narrative: Guillain-Barre Syndrome with progressive weakness and numbness over several days. Had ED visits 10/8, 10/10, 10/11. Admitted to hospital on 10/13/21. Required intubation and mechanical ventilation on 10/14/2021. Patient had received Moderna COVID 19 vaccine on 9/15/21.
Sex: M
Vaccine: COVID19
Symptoms: Unevaluable event
Clinical narrative: I went to get Covid-19 booster vaccine (pfizer, lot # FH8028) at Pharmacy. The predrawn vaccine in 1ml syringes are on table at room temparature. When asked the storage protocols the store following, pharmacist said they are following the standard protocols. I just want to make sure storage and vaccination protocols, especially temparature controls are followed properly. mRNA vaccine are very sensative to store temparatures. Any deviation will make vaccine useless. I am expecting a vaccine specialist, from FDA, to follow up with this sore in particular and Pharmacy in general to verify the vaccine distribution, storage and administration protocols to protect the public health.
Sex: U
Vaccine: HEP
Symptoms: Product dispensing error, Recalled product administered
Clinical narrative: lot number involved in a RECALL was administered; lot number involved in a RECALL was administered; This case was reported by a nurse via call center representative and described the occurrence of recalled drug administered in a patient who received HBV (Engerix B) (batch number CP23D, expiry date 31st December 2023) for prophylaxis.   On an unknown date, the patient received Engerix B. On an unknown date, unknown after receiving Engerix B, the patient experienced recalled drug administered and drug dispensing error. On an unknown date, the outcome of the recalled drug administered and drug dispensing error were unknown.  Additional details provided were as follows: The age at vaccination was not reported. The nurse would like to know if 10 patients received Engerix-B of lot number CP23D and healthcare professional was sure that 10 patients received the vaccine because they completed the full vaccine box. The patient received recalled dose of Engerix B which led to recalled drug administered and drug dispensing error. Immediately all the product was quarantined from this lot. The product was stopped distributing and administering this lot only. The nurse asked do we need to inform patients and revaccinate them. The reporter consented to follow-up. This case was 1 of 10 linked cases, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR223915:same reporter US-GLAXOSMITHKLINE-US2021AMR223914:same reporter US-GLAXOSMITHKLINE-US2021222775:same reporter US-GLAXOSMITHKLINE-US2021AMR223919:same reporter US-GLAXOSMITHKLINE-US2021AMR223916:same reporter US-GLAXOSMITHKLINE-US2021AMR223912:same reporter US-GLAXOSMITHKLINE-US2021AMR223918:same reporter US-GLAXOSMITHKLINE-US2021AMR223917:same reporter US-GLAXOSMITHKLINE-US2021AMR223913:same reporter
Sex: U
Vaccine: HEP
Symptoms: Product dispensing error, Recalled product administered
Clinical narrative: lot number involved in a RECALL was administered; lot number involved in a RECALL was administered; This case was reported by a nurse via call center representative and described the occurrence of recalled drug administered in a patient who received HBV (Engerix B) (batch number CP23D, expiry date 31st December 2023) for prophylaxis.   On an unknown date, the patient received Engerix B. On an unknown date, unknown after receiving Engerix B, the patient experienced recalled drug administered and drug dispensing error. On an unknown date, the outcome of the recalled drug administered and drug dispensing error were unknown.  Additional details provided were as follows: The age at vaccination was not reported. The patient received recalled dose of Engerix B which led to recalled drug administered and drug dispensing error. Immediately all the product were quarantined from this lot. The product was stopped distributing and administering this lot only. The nurse asked if they need to inform patients and revaccinate them. The reporter consented to follow-up. This case is one of 10 case, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR223912:same reporter US-GLAXOSMITHKLINE-US2021AMR223918:same reporter US-GLAXOSMITHKLINE-US2021222775:same reporter US-GLAXOSMITHKLINE-US2021AMR223917:same reporter US-GLAXOSMITHKLINE-US2021AMR223913:same reporter US-GLAXOSMITHKLINE-US2021AMR223920:same reporter US-GLAXOSMITHKLINE-US2021AMR223916:same reporter US-GLAXOSMITHKLINE-US2021AMR223915:same reporter US-GLAXOSMITHKLINE-US2021AMR223914:same reporter
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Angioedema, Periorbital oedema, Periorbital swelling, Rash, Swelling
Clinical narrative: Shortly after  the short I developed a fluid filled bubble under my right eye (less than 4 hours post vaccine).  In the subsequent hours and days, I developed angioedema, urticaria and increased asthma symptoms.  I contacted and was placed on oral prednisone.     Since then, I've had reoccurrence of the 3 above mentioned symptoms.  I still feel like I have residual effects, including strange sensations on my right side face.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Swelling face
Clinical narrative: Shortly after  the short I developed a fluid filled bubble under my right eye (less than 4 hours post vaccine).  In the subsequent hours and days, I developed angioedema, urticaria and increased asthma symptoms.  I contacted and was placed on oral prednisone.     Since then, I've had reoccurrence of the 3 above mentioned symptoms.  I still feel like I have residual effects, including strange sensations on my right side face.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Angioedema, Asthma, Blister, Facial discomfort, Urticaria
Clinical narrative: Shortly after  the short I developed a fluid filled bubble under my right eye (less than 4 hours post vaccine).  In the subsequent hours and days, I developed angioedema, urticaria and increased asthma symptoms.  I contacted and was placed on oral prednisone.     Since then, I've had reoccurrence of the 3 above mentioned symptoms.  I still feel like I have residual effects, including strange sensations on my right side face.
Age: 42.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Headache, Immediate post-injection reaction, Nausea
Clinical narrative: felt dizzy; lightheaded; Nausea; This is a spontaneous report from a contactable Pharmacist. This Pharmacist reported for a 42-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: EL3246, Expiry Date was not provided), via an intramuscular route of administration, on 29Jan2021 at 13:45 (age at vaccination was 42-Years) as DOSE 1, SINGLE for COVID-19 immunization. It was unknown that Patient was pregnant at the time of vaccination. Medical history included Migraine. Patient received Fish oil capsules as other mediation in two weeks. Patient had known allergies from ceftriaxone (nausea, diaphoresis), Imitrex, nitrofurantoin (rash, nausea/vomiting, headache from an unknown date and unknown if ongoing. Patient after receiving her vaccine stated she felt dizzy and lightheaded with nausea immediately. Patient taken to first aid area for assessment. Patient is A & O x3, Skin Pink warm and dry and patient appeared in no apparent distress. Patients VS were: B/P 130/66, HR 89, SaO2 of 95% on RA. Patient stated that she did have a headache with 6/10 pain and stated her last migraine was last one week ago with no aura. Patient discharged home after full 30 minute wait without complications and return to baseline. The patient did not receive any other vaccines in four weeks. It was unknown that Patient had COVID prior vaccination. It was unknown that patient tested COVID post vaccination. AE did not result in anything. Patient did not receive treatment for any event. The outcome of all events was resolved on an unspecified date in 2021.
Age: 42.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood pressure measurement, Dizziness, Headache, Heart rate, Nausea
Clinical narrative: felt dizzy; lightheaded; Nausea; This is a spontaneous report from a contactable Pharmacist. This Pharmacist reported for a 42-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: EL3246, Expiry Date was not provided), via an intramuscular route of administration, on 29Jan2021 at 13:45 (age at vaccination was 42-Years) as DOSE 1, SINGLE for COVID-19 immunization. It was unknown that Patient was pregnant at the time of vaccination. Medical history included Migraine. Patient received Fish oil capsules as other mediation in two weeks. Patient had known allergies from ceftriaxone (nausea, diaphoresis), Imitrex, nitrofurantoin (rash, nausea/vomiting, headache from an unknown date and unknown if ongoing. Patient after receiving her vaccine stated she felt dizzy and lightheaded with nausea immediately. Patient taken to first aid area for assessment. Patient is A & O x3, Skin Pink warm and dry and patient appeared in no apparent distress. Patients VS were: B/P 130/66, HR 89, SaO2 of 95% on RA. Patient stated that she did have a headache with 6/10 pain and stated her last migraine was last one week ago with no aura. Patient discharged home after full 30 minute wait without complications and return to baseline. The patient did not receive any other vaccines in four weeks. It was unknown that Patient had COVID prior vaccination. It was unknown that patient tested COVID post vaccination. AE did not result in anything. Patient did not receive treatment for any event. The outcome of all events was resolved on an unspecified date in 2021.
Age: 42.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Oxygen saturation
Clinical narrative: felt dizzy; lightheaded; Nausea; This is a spontaneous report from a contactable Pharmacist. This Pharmacist reported for a 42-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: EL3246, Expiry Date was not provided), via an intramuscular route of administration, on 29Jan2021 at 13:45 (age at vaccination was 42-Years) as DOSE 1, SINGLE for COVID-19 immunization. It was unknown that Patient was pregnant at the time of vaccination. Medical history included Migraine. Patient received Fish oil capsules as other mediation in two weeks. Patient had known allergies from ceftriaxone (nausea, diaphoresis), Imitrex, nitrofurantoin (rash, nausea/vomiting, headache from an unknown date and unknown if ongoing. Patient after receiving her vaccine stated she felt dizzy and lightheaded with nausea immediately. Patient taken to first aid area for assessment. Patient is A & O x3, Skin Pink warm and dry and patient appeared in no apparent distress. Patients VS were: B/P 130/66, HR 89, SaO2 of 95% on RA. Patient stated that she did have a headache with 6/10 pain and stated her last migraine was last one week ago with no aura. Patient discharged home after full 30 minute wait without complications and return to baseline. The patient did not receive any other vaccines in four weeks. It was unknown that Patient had COVID prior vaccination. It was unknown that patient tested COVID post vaccination. AE did not result in anything. Patient did not receive treatment for any event. The outcome of all events was resolved on an unspecified date in 2021.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Body temperature, Headache, Insomnia, Pain, Pain in extremity
Clinical narrative: the next day she was running a little fever for a couple of hours and the fever came back with the temperature of 100°C; pain in the arm; couldn't sleep the first night after receiving the 2nd shot; the facility mistakenly administered saline from the vials; She mentioned that she feels achy and tired; She mentioned that she feels achy and tired; This is a spontaneous report from a contactable consumer or other non hcp (patient herself) from a Pfizer Sponsored Program Support. A female patient of an unspecified age received BNT162B2 (PFIZER BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on 31Mar2021 as dose 2, single for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient previously received BNT162B2 (PFIZER BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on 10Mar2021 as dose 1, single for COVID-19 immunization. It was reported she experienced the normal reaction after receiving the 2nd shot; pain in the arm, couldn't sleep the first night after receiving the 2nd shot on 31Mar2021, the next day she was running a little fever for a couple of hours and the fever came back with the temperature of 100 degrees centigrade on 01Apr2021. On an unspecified date in 2021 she mentioned that she feels achy and tired. She stated she received a phone call yesterday from the facility where she received the vaccine stating that they need to be revaccinated. The facility informed her that 10 out of the 100 people who took the 2nd shot, the facility mistakenly administered saline from the vials on 13Apr2021. Stated that the 10 people got the saline vial which they need to do it again for the people who took the covid vaccine. Concerned if she should get the 3rd shot on 31Apr. because she had a normal reaction (side effects) and she might have a severe reaction if she would be revaccinated. Seriousness of the events was non serious. The patient underwent lab tests and procedures which included temperature (body temperature): 100 degrees centigrade on 01Apr2021. The outcome of all the events was unknown. No follow-up attempts are possible. Information about lot/batch number cannot be obtained.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pyrexia, Restlessness, Vaccination site pain, Wrong product administered
Clinical narrative: the next day she was running a little fever for a couple of hours and the fever came back with the temperature of 100°C; pain in the arm; couldn't sleep the first night after receiving the 2nd shot; the facility mistakenly administered saline from the vials; She mentioned that she feels achy and tired; She mentioned that she feels achy and tired; This is a spontaneous report from a contactable consumer or other non hcp (patient herself) from a Pfizer Sponsored Program Support. A female patient of an unspecified age received BNT162B2 (PFIZER BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on 31Mar2021 as dose 2, single for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient previously received BNT162B2 (PFIZER BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on 10Mar2021 as dose 1, single for COVID-19 immunization. It was reported she experienced the normal reaction after receiving the 2nd shot; pain in the arm, couldn't sleep the first night after receiving the 2nd shot on 31Mar2021, the next day she was running a little fever for a couple of hours and the fever came back with the temperature of 100 degrees centigrade on 01Apr2021. On an unspecified date in 2021 she mentioned that she feels achy and tired. She stated she received a phone call yesterday from the facility where she received the vaccine stating that they need to be revaccinated. The facility informed her that 10 out of the 100 people who took the 2nd shot, the facility mistakenly administered saline from the vials on 13Apr2021. Stated that the 10 people got the saline vial which they need to do it again for the people who took the covid vaccine. Concerned if she should get the 3rd shot on 31Apr. because she had a normal reaction (side effects) and she might have a severe reaction if she would be revaccinated. Seriousness of the events was non serious. The patient underwent lab tests and procedures which included temperature (body temperature): 100 degrees centigrade on 01Apr2021. The outcome of all the events was unknown. No follow-up attempts are possible. Information about lot/batch number cannot be obtained.